Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Stroke. 2014 Jan 14;45(3):828–834. doi: 10.1161/STROKEAHA.113.003754

Fig 2. SD208 reduces GMH-induced phosphorylation of TGFR-I downstream molecules, SMAD 2/3.

Fig 2

(A) Neither GMH nor SD208 had any apparent effect on SMAD 2/3 level evaluated 3 days after GMH. (B) SMAD 2/3 phosphorylation at day 3 was increased in GMH (N=6) animals compared to sham-operated (N=6) animals. Both low (N=6) and high (N=6) SD208 doses decreased GMH-induced phosphorylation of SMAD 2/3. (C) Only the high dose of SD208 decreased the ratio of phosphorylated/non-phosphorylated SMAD 2/3 at day 3. (* p<0.05 vs. sham, # p<0.05 vs. vehicle). Values are expressed as mean± SD.